Novo Nordisk announced Friday that ziltivekimab — a drug engineered specifically to suppress the inflammatory protein IL-6 — achieved exactly what it was designed to achieve: it reliably cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results